Company intelligence / Profile preview

Leukos Biotech

Barcelona, Catalonia, Spainleukosbiotech.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Leukos Biotech’s lead compound, LB208/AOP208, a first-in-class orally available HTR1B antagonist targeting cancer stem cells and chemoresistant tumor cells, has shown promising preclinical results with high selectivity for malignant over normal cells. The compound entered its first Phase I clinical trial in advanced solid tumors in late 2023. Additional trials are planned for hematological malignancies such as AML.

Therapeutic areas: OncologyHematology
Modalities: Small molecules (notably LB208/AOP208)Monoclonal antibodies (as biomarkers/diagnostics)
Industry: Biotech

Drug pipeline

1 asset

LB208

Phase 2

Indications: Acute myeloid leukemia

Partnerships

AOP Health Group—co-development agreement covering further development of LB208/AOP208 across multiple indications including rare diseases and oncology

Beyond the preview

Go deeper on Leukos Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leukos Biotech.

Explore the full profile